Search PubMed⌕ Search

Biomedical subjects

I N Bokarev

Publications and source records attributed to I N Bokarev.

At least 19 recordsLinked to original sources
PubMed2006

[Present-day problems of venous thromboses].

Venous thrombosis (VT) is a frequent pathology associated with a high mortality. A high risk of VT is associated with a variety of diseases, syndromes, and situations, connected with a congenital predisposition (thrombophilia) or not. Clinical and instrumental data in VT are non-specific. The diagnosis of these conditions is very difficult. Correct and timely treatment decreases mortality associated with pulmonary arterial thromboembolism (PATE). Unfortunately, this index is still very high: a lot of patients die within first minutes and even seconds of the moment of pulmonary arterial obturation with a thrombus. All this suggests that PATE belongs to diseases that are easier to prevent than to treat. In connection with this, a doctor examining a patient must always keep the possibility of VT and PATE in mind and evaluate the risk of their development, thus taking a decision concerning the necessity, duration, and a method of preventive treatment.

Humans↗
PubMed2006

[Thrombus precursor protein (soluble monomeric protein) in patients with acute coronary syndrome].

The purpose of the study was to determine the level of thrombus precursor protein (TrP) in patients with acute coronary syndrome (ACS). Twenty-six patients with ACS and anginal pain experienced during 2 to 12 hours (7.2 +/- 1.3 hours), admitted to cardiological intensive care unit, were enrolled in the study. Five ml of blood were sampled from a cubital vein of all the patients during the phase of the most intensive pain. TrP blood levels were measured with ELISA, Enzyme-Linked Immunoadsorbent Assay. The control group consisted of 29 healthy volunteers and 22 patients with stable exertional stenocardia. A significant increase in TpR (7.2 +/- 1.45 mcg/ml) was noted in the ACS patients as early as during the first 6 hours, vs. the healthy controls (1.01 +/- 0.12 mcg/ml) and the patients with stable stenocardia (1.21 +/- 0.06 mcg/ml), p < 0.01. A high level of TrP in the ACS patients could be noted earlier than a diagnostically significant increase in creatine phosphokinase level. No direct correlation was observed between the TrP level and the dynamics of such indices of the procoagulatory hemocoagulation chain as fibrinogen, prothrombin index, and active partial thromboplastin time. The results of the study demonstrate that the measurement of TrP level is highly informative when the intensity of intravascular blood coagulation in ACS patients is to be evaluated, which can be used to clarify indications to anticoagulation therapy. The enzyme immune method of TrP detection in the plasma of ACS patients can be recommended for clinical application.

Acute Disease↗
PubMed2005

[The soluble fibrin monomer in patients with instable angina].

The purpose of the study was to measure the blood level of thrombus precursor protein (TpP), a soluble fibrin monomer, in patients with stable exertional angina (SEA) and healthy people. The study included the examination of 33 patients with SEA (functional class II and III) and 29 practically healthy volunteers (control group). The detection of TpP in blood plasma was performed by solid-phase immune-enzyme analysis ("sandwich" type) using commercial diagnosticum "Kit" ("ABS", USA) and a microplate reader "IEMS Analyzer\Dispenser, with automatic result calculation in "Logistic fif" mode. TpP level in patients with SEA on the average was slightly higher than in control group, but the difference was not significant. TpP blood level was independent of the patients' gender, age, angina functional class and an old myocardial infarction. TpP blood level in patients with SEA depended on the duration of the illness, and proved to be significantly higher (compared with that in control group) in patients with SEA during the first 5 years of the illness, i.e. at early stages of CHD. Solid-phase immune-enzyme analysis ("sandwich" type) is a highly informative and affordable clinical method. TpP level in patients with SEA on the average was slightly higher than in healthy people (1.21 +/- 0.06 mkg/ml and 1.01 +/- 0.12 mkg/ml, respectively), but the difference was significant only in patients during the first 5 years of having SEA (1.41 +/- 0.11 mkg/ml).

Adult↗
PubMed2002

[Diagnostic and therapeutic problems in adult onset Still's disease (data of a long-term follow-up)].

15 patients with Still's disease of adults (SDA) were followed up for 17 years maximum. The disease showed a principal clinical-laboratory syndrome observed both in SDA debut and exacerbations (recurrences). Clinical manifestations of SDA do not arise stereotypically causing difficulties in its nosological interpretation. SDA course is represented by three variants: monophasic (monocyclic), recurrent and chronic persisting with development of destructive arthritis. Use of nonsteroid antiinflammatory drugs is analysed, indications to administration of glucocorticoids and basic treatment are listed. Reversibility of systemic SDA manifestations except the articular one is shown. About half of the patients develop chronic destructive arthritis. In active SDA, renal amyloidosis and chronic renal failure may develop with lethal outcome.

Adolescent↗
PubMed2002

[Thrombophilia, venous thromboses and their treatment].

Thromboses are leading among causes of death worldwide. Arterial thromboses--the underlying cause of myocardial infarctions, strokes and acute ischemia--develop due to a defect of atherosclerotic plaque. Venous thromboses and associated venous thromboembolism killing one of 1000 world population develop in unaffected vascular wall. Recent data show that 70% cases of venous thromboembolism can be prevented by identification of thrombophilia markers--inheritable conditions associated with thromb formation. Current information on variants and prevalence of thrombophilia is given as well as recommendations on venous thromboembolism prevention.

Anticoagulants↗
PubMed2000

[Telomerase--new diagnostic and therapeutic options in oncology].

One of the new directions in study of malignant tumor pathogenesis is telomerase theory. Investigations in the culture of human cells have shown that telomerase activation can lead to tumor development. Prospective investigations of telomerase could be able to supplement the data about tumor pathomorphology and will permit to conduct monitoring on patients with malignant tumors by studying telomerase in fractionated cells from different body tissues and biological media. Telomerase inhibitors are possible drugs for antitumoral therapy. It is supposed that the abovementioned agents will decrease telomerase activity of proliferating tumoral cells that will cause destabilization of their genome, stopping of proliferation and death of tumoral clone.

Biomarkers, Tumor↗